Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Phase 1

Recruiting

• Conditions: Chronic Kidney Diseases; Heart Failure; Heart Failure with Preserved Ejection Fraction; Kidney Diseases
• Interventions: Drug: Dapagliflozin 10 MG [Farxiga]

• Registration Number: NCT05719714
• Lead Sponsor: Northwestern University

Brief Summary

The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

Detailed Description

This is a 6-month interventional patient-oriented research study of sixty patients with chronic kidney disease (CKD) and evidence of subclinical heart failure with preserved ejection fraction (HFpEF) (estimated glomerular filtration rate \[eGFR\] 25-60 ml/min/1.73m2, absolute left ventricular longitudinal strain \[LVGLS\] \<18% or left atrial reservoir strain (LARS) \< 25% on 2D-speckle tracking echocardiography or meeting 3/5 of the American Society of Echocardiography criteria for diastolic dysfunction: septal e' \<7 cm/sec, lateral e'\<10 cm/sec, average E/e' ratio\>14, left atrial volume index \>34 mL/m2, or peak tricuspid regurgitation velocity \>2.8 m/sec), or peak VO2 Females: ≤ 18 mL/kg/min, peak VO2 Males: ≤ 20 mL/kg/min on cardiopulmonary exercise testing, or lack of augmentation of LVLS or LARS during exercise. Half of the patients will be randomized to receive dapagliflozin for six months as an add-on to standard of care (SOC). Metabolomic testing and cardiac and functional exercise testing will be done at baseline and at six months. The aim of the current study is to investigate whether SGLT2i-induced metabolomic changes are associated with improved cardiac and functional testing ascertained on 2D-speckle tracking echocardiography or cardiopulmonary functional testing at six months.

Study Timeline

• Study First Submitted: 2023-01-31
• Study First Submitted QC: 2023-01-31
• Study First Posted: 2023-02-09
• Study Start: 2024-01-16
• Status Verified: 2024-05
• Last Update Submitted: 2025-03-26
• Last Update Posted: 2025-04-01
• Primary Completion: 2026-03-01
• Study Completion: 2026-09-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. >18 years of age
2. eGFR 25-60 ml/min/1,73m2 (eGFR = estimated glomerular filtration rate)
3. On stable doses of diuretics and/or angiotensin converting enzyme inhibitor or angiotensin receptor blocker
4. Evidence of subclinical heart failure with preserved ejection fraction at their pre-exercise echocardiogram (defined as meeting 3/5 of the American Society of Echocardiography (ASE) criteria for diastolic dysfunction [septal e'<7 cm/wc, average E/e' ratio>14, left atrial volume index >34 mL/m2, and peak TR velocity >2.8 m/sec] or absolute left ventricular longitudinal strain < 18%, left atrial reservoir strain (LARS) < 25% on 2d speckle tracking echocardiography), lack of augmentation of LVLS or LARS during exercise, or peak VO2 Females: ≤ 18 mL/kg/min, peak VO2 Males: ≤ 20 mL/kg/min on cardiopulmonary exercise testing.

Exclusion Criteria

1. presence or history of diabetes
2. coronary revascularization within the last 6 months
3. hemodynamically significant valvular disease
4. significant lung disease requiring home oxygen
5. angina (chest pain)
6. non-revascularized myocardial ischemia
7. systolic BP <100 or >180 mmHg
8. pregnancy
9. clinical heart failure symptoms
10. history of systemic disease processes that can cause HFpEF such as amyloidosis or sarcoidosis
11. any musculoskeletal or chronic condition that will interfere with completion of cardiac testing
12. active cancer
13. immunosuppressive therapy
14. baseline or pre-exercise echocardiogram demonstrates a reduced ejection fraction < 50%
15. currently on sodium glucose cotransporter 2 inhibitor (SGLT2i) therapy
16. Hypersensitivity to a SGLT2i
17. Pre-existing liver disease
18. ALT/AST> 3x normal (ALT = alanine aminotransferase AST = aspartate aminotransferase)
19. history of recurrent urinary tract infections (in the opinion of the investigator) or a urinary tract infection in the last 3 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Intervention group	Dapagliflozin 10 MG [Farxiga]	Thirty individuals will be randomized to dapagliflozin 10mg to be taken daily for six months.

Primary Outcome Measures

Name	Time	Method
Circulating plasma metabolite concentrations	6 months	Plasma
Peak VO2 (oxygen consumption)	6 months	Cardiopulmonary exercise stress test
Left ventricular longitudinal strain (LVLS)	6 months	2D-speckle tracking echocardiography

Secondary Outcome Measures

Name	Time	Method
Right ventricular free wall strain	6 Months	2D-STE
Left Atrial Reservoir Strain (LARS)	6 months	2D-STE

Trial Locations

Locations (1)

Northwestern University; 🇺🇸 Chicago, Illinois, United States